Skip to main content
China Resources Boya Bio-pharmaceutical Group Co., Ltd logo

China Resources Boya Bio-pharmaceutical Group Co., Ltd — Investor Relations & Filings

Ticker · 300294 ISIN · CNE100001FF1 LEI · 836800D4KUVERU6C7D85 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,342 across all filing types
Latest filing 2026-05-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300294

About China Resources Boya Bio-pharmaceutical Group Co., Ltd

https://www.china-boya.com

China Resources Boya Bio-pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of blood products and plasma-derived medicinal products. The company operates an integrated value chain encompassing plasma collection, fractionation, and pharmaceutical manufacturing. Its core product portfolio includes human albumin, intravenous immunoglobulin (IVIG), and various coagulation factors such as Factor VIII and prothrombin complex. The organization focuses on therapeutic areas including immunology, hematology, and critical care. By leveraging advanced purification technologies and a network of plasma donation centers, the company provides essential treatments for rare diseases and emergency medical needs. Its operations are characterized by rigorous quality control standards and a commitment to innovation in biopharmaceutical processing and therapeutic development.

Recent filings

Filing Released Lang Actions
关于公司董事暨副总裁辞任的公告
Board/Management Information Classification · 93% confidence The document is an official announcement of the resignation of a company director and vice-president, detailing board changes (management changes), and referencing compliance with corporate law and stock exchange guidelines. This aligns with the category for Board/Management Information (MANG).
2026-05-15 Chinese
公司2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 88% confidence The document is an announcement of the company’s 2025 profit distribution (cash dividend) implementation, specifying dividend per share, record date, ex-dividend date, payment method, and related details. This matches the definition of a Notice of Dividend Amount (DIV).
2026-05-13 Chinese
公司关于变更办公地址及投资者联系电话的公告
Regulatory Filings Classification · 80% confidence The document is a public announcement (“公告”) by the company regarding the change of its office address and investor contact telephone number. It does not present financial results, request shareholder votes, describe a report, or involve M&A, dividends, board changes, or share transactions. It is a general regulatory announcement that falls into the fallback category for miscellaneous compliance filings. Therefore, it should be classified as a Regulatory Filings (RNS).
2026-05-13 Chinese
公司关于参加江西辖区上市公司2026年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by a regional stock company association. It invites investors to join a scheduled online interaction session. The document is short (458 characters) and does not contain any financial data, report content, or detailed presentation materials. It is an announcement of an event related to investor relations rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-05-08 Chinese
公司关于转让南京新百药业股份有限公司100%股权暨关联交易的公告
M&A Activity Classification · 85% confidence The document is a detailed announcement of a related‐party transaction disposing of 100% equity of a subsidiary (南京新百药业有限公司), including transaction parties, pricing policy, agreement terms, internal approvals, auditor and appraiser opinions, and regulatory compliance. It is not an annual report, earnings release, or simple publication notice but a specific M&A transaction disclosure. This fits the M&A Activity category (TAR).
2026-04-24 Chinese
公司关于会计政策变更的公告
Regulatory Filings Classification · 85% confidence The document is an official announcement by a listed company regarding a change in accounting policy driven by a new Ministry of Finance interpretation, referencing exchange listing rules and stating no board or shareholder approval is required. It is not a full financial report, earnings release, or presentation but a regulatory disclosure of policy change. It therefore falls under general regulatory filings (RNS).
2026-04-24 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.